Format

Send to

Choose Destination
Cancer Cell. 2014 Mar 17;25(3):318-34. doi: 10.1016/j.ccr.2014.02.018.

From fly wings to targeted cancer therapies: a centennial for notch signaling.

Author information

1
Howard Hughes Medical Institute and Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; NYU Cancer Institute and Helen L. and Martin S. Kimmel Center for Stem Cell Biology, NYU School of Medicine, New York, NY 10016, USA.
2
Departments of Pediatrics and Genetics, Stanford University, Stanford, CA 94305, USA.
3
Departments of Pediatrics and Genetics, Stanford University, Stanford, CA 94305, USA. Electronic address: julsage@stanford.edu.
4
Howard Hughes Medical Institute and Department of Pathology, NYU School of Medicine, New York, NY 10016, USA; NYU Cancer Institute and Helen L. and Martin S. Kimmel Center for Stem Cell Biology, NYU School of Medicine, New York, NY 10016, USA. Electronic address: iannis.aifantis@nyumc.org.

Abstract

Since Notch phenotypes in Drosophila melanogaster were first identified 100 years ago, Notch signaling has been extensively characterized as a regulator of cell-fate decisions in a variety of organisms and tissues. However, in the past 20 years, accumulating evidence has linked alterations in the Notch pathway to tumorigenesis. In this review, we discuss the protumorigenic and tumor-suppressive functions of Notch signaling, and dissect the molecular mechanisms that underlie these functions in hematopoietic cancers and solid tumors. Finally, we link these mechanisms and observations to possible therapeutic strategies targeting the Notch pathway in human cancers.

PMID:
24651013
PMCID:
PMC4040351
DOI:
10.1016/j.ccr.2014.02.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center